Hematology

The associate attending physician at Memorial Sloan Kettering Cancer Center discussed further research that remains to be conducted with the allogeneic cell therapy.

GC012F recently showed efficacy in newly-diagnosed MM in investigator-initiated trials.

The assistant member of the department of malignant hematology at Moffitt Cancer Center discussed updated data on the allogeneic CAR T therapy, UNICART123v1.2.

Review top news and interview highlights from the week ending February 3, 2023.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

AB-101 is also being investigated with the innate cell engager AFM13 for CD30 lymphomas.

Positive preclinical data related to SENTI-202 and SENTI-401 were presented at conferences last year.

Sana Biotechnology also plans to submit another IND for the same indications for a CD22-targeted CAR T later in 2022.

Cilta-cel demonstrated a significant improvement in progression-free survival over standards of care.

Review top news and interview highlights from the week ending January 27, 2023.

The chief executive officer and president of Eterna Therapeutics discussed the company’s new collaboration with the University of Texas MD Anderson Cancer Center.

Breyanzi is currently approved for the second-line or later treatment of large B-cell lymphomas.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The CD19/CD20 dual-targeted CAR is currently under investigation in an investigator-initiated study in UCLA.

The dosing of the first patient took place in December 2022 and no adverse events related to the therapy have been reported.

With confidence building, numerous cell and gene therapies will likely go before the FDA and other global regulatory agencies this year, in addition to key data readouts.

The associate professor of medicine at University of Pennsylvania discussed new data from the BENEGENE-2 study of fidanacogene elaparvovec.

Review top news and interview highlights from the week ending January 20, 2023.

The company is reprioritizing to focus on its clinical stage programs, which ran into a number of setbacks in 2022.

Steven Pipe, MD, CS Mott Children’s Hospital, discussed the latest follow-up data from the HOPE-B study of the approved therapy, Hemgenix.

The chief executive officer of Cartherics discussed the company’s development of NK cell, T-cell, and macrophage cell therapies for various solid tumor indications.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The assistant member of the bone marrow transplant department at St. Jude Children’s Research Hospital discussed advantages of OTQ923 in treating SCD.

Poolbeg Pharma’s POLB 001 previously showed promise in a lipopolysaccharide human challenge trial.

The associate professor of medicine at Siteman Cancer Center and WUSTL discussed further research to be done with CAR T-cell therapies.